Latest News & Features
Big Pharma
Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands. 26 November 2013
Americas
The US Food and Drug Administration has told genetics company 23andMe to stop selling its Personal Genome Service product immediately. 26 November 2013
Americas
The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015. 20 November 2013
Americas
Cadence Pharmaceuticals announced on November 14 that the US District Court for the District of Delaware ruled in its favour in its patent infringement suit against Exela Pharma Sciences LLC. 19 November 2013
Europe
Kevin Mooney, chairman of the drafting committee for the Unified Patent Court (UPC)’s rules of procedure, explained the current state of play to the CIPA Life Sciences conference. 15 November 2013
Europe
The EPO boards of appeal are unlikely to be able to reduce the case backlog anytime soon, but attorneys should be wary of possible changes in board practice, former board head Alec Clelland told the CIPA Life Sciences conference. 14 November 2013
Americas
The FTC has issued final changes to the premerger notification rules that require pharmaceutical companies to report certain proposed patent right acquisitions to the commission and US Department of Justice for antitrust review. 13 November 2013
Americas
Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP. 13 November 2013
Americas
The US District Court for the Northern District of California has dismissed biosimilar maker Sandoz’s motion for declaratory judgment that its etanercept product does not infringe biopharmaceutical company Amgen’s arthritis drug Enbrel. 13 November 2013
Americas
UK-based drugmaker Shire plc announced on November 11 that it had acquired rare disease biopharmaceutical company ViroPharma in an agreement worth approximately $4.2 billion. 12 November 2013